Funding | BEAM Alliance



EU: HORIZON2020 Call - Modelling the impact of monoclonal antibodies and vaccines on the reduction of AMR

EU: HORIZON2020 Call – Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance

Vaccines and monoclonal Antibodies (mAb) may reduce antimicrobial resistance (AMR). However, individual vaccine developers and manufacturers, as well as organisations developing mAbs and health authorities, acting alone, do not have the resources and the full expertise required to make a realistic and comparable assessment of the use of the different products on the reduction of AMR. This could instead be possible through the development of a mathematical model. For such a model to be representative of the concerns and interests of the various actors (i.e. industry and the public health sector), it should take into account the perspectives of these different actors in order to capture all relevant impacts both in terms of costs and health outcomes.

1) Evaluate the burden of disease of AMR by estimating inpatients’ (acute care hospitals and long-term care facilities) and outpatients’ infection rates in at least 8 EU countries for which suitable data is collected and available, as well as in the US , and the relative attributable risk for morbidity, mortality and costs.
2) Build a comprehensive AMR model (i.e. model structure, parameters, assumptions) based on an analysis of the strengths and weaknesses of existing models, and a gap analysis.
3) Collecting, gathering, and analysing data from existing databases to feed the model.
4) Develop and test a cost-effectiveness analysis (CEA) to estimate the cost and benefits of covering defined target groups (e.g. 18+, 60+, surgeries) with mAbs and vaccines.
5) Set up a study to test, monitor, evaluate and improve the model.
6) Ensure a public and broad access to the model

Opening:23 June 2020
Deadline:29 September 2020 (17:00:00 Brussels time)
2nd stage Deadline:17 March 2021 (17:00:00 Brussels time)

More information available here

Horizon2020 SME Instrument

EU: Horizon2020 SME Instrument

SCOPE: The SME Instrument supports high-risk, high-potential small and medium-sized enterprises to develop and bring to market new products, services and business models that could drive economic growth. The SME Instrument is for innovators with ground-breaking concepts that could shape new markets or disrupt existing ones in Europe and worldwide.

The SME Instrument provides full-cycle business innovation support. It has three phases, including a coaching service.
1. Feasibility study: Phase 1
2. From concept to market: Phase 2
3. Commercialisation: Phase 3

Opening date: 7 November 2017
Cut-off dates: Multiple (until oct/nov 2020)

More information available here


World: CARB-X, Combating Antibiotic Resistant Bacteria

SCOPE: CARB-X welcomes applications from around the world for funding and support for the early development of antibiotics, diagnostics, vaccines, devices and other products to combat the most serious drug-resistant bacteria.

KEY DATES & APPLICATION: New Funding Rounds launched!

  • Funding Round 1: NON-TRADITIONAL Approaches – June 3, 2019 through June 10, 2019, 5 pm ET
  • Funding Round 2: VACCINES and BIOTHERAPEUTICS – July 8, 2019, through July 15, 2019, 5 pm ET
  • Funding Round 3: DIAGNOSTICS – August 12, 2019, through August 19, 2019, 5 pm ET
  • Funding Round 4: DIRECT ACTING SMALL MOLECULES – November 12, 2019, through November 19, 2019, 5 pm ET

More information available here


EU: Call for Tender “Antisuperbugs”

EU: Call for Tender “Antisuperbugs”

SCOPE: Six leading European procuring entities under the lead of AQuAS challenge the industry to develop a smart ICT solutions able to detect the presence of resistant microorganisms, give real-time feedback to the user and at the same time share the information with the healthcare provider electronic record systems linking the infection with the place of the detection.
The available budget for the research, development and testing of these innovative solutions is 3.45 million Euro (VAT included).

The call for tender has been published on the 26th of July 2019.
The deadline for submission of proposals will be on the 28th of October 2019.

More information available on the TED platform and the public procurement platform.

InnovFin Infectious Diseases

EU: InnovFin Infectious Diseases (IDFF)

SCOPE: The InnovFin Infectious Diseases Finance Facility (IDFF) provides financial products ranging from standard debt to equity-type financing for amounts typically between EUR 7.5 million and EUR 75 million, to innovative players active in developing innovative vaccines, drugs, medical and diagnostic devices or novel research infrastructures for combatting infectious diseases. Project costs may include clinical trial costs, set-up of commercialisation such as market access, development of prototypes or industrial roll-out of novel equipment, pre-clinical R&D costs and working capital requirement. The product is being made available directly through the European Investment Bank.


More information available here

DRIVe BARDA initiative / DRIVe-X

World: DRIVe BARDA initiative / DRIVe-X

SCOPE: The Biomedical Advanced Research and Development Authority (BARDA) serves the US nation by partnering with industry to make available medical countermeasures against wide range of major threats to the health security. DRIVe (Division of Research, Innovation, and Ventures) is a bold new approach to achieving once-unthinkable solutions to health security challenges – through the power of collaboration and innovation. DRIVe PPP will provide non-dilutive and dilutive funding opportunities to Companies (DRIVe-X), VCs (Ventures V), non-for-profit third parties (LAUNCH) and regional accelerators (ACCELERATORS).

SEPSIS: new technologies to aid in restoring patients’ homeostasis. 

ENACT (Early Notification to Act, Control and Treat): closing the gap between diagnosis and treatment by leveraging advanced data analytics and algorithms coupled with innovative detection modalities. 

Other areas: creating universal treatment options for broad classes of pathogens, ensuring access to life-saving medical countermeasures, and transforming medical countermeasure development by eradicating animal testing (non-exhaustive).

More information available here

DRIVe EZ-BAA Notice details available here

New drugs and vaccines for priority pathogens in antimicrobial resistance 2019 ( EDCTP )

WORLD:  New drugs and vaccines for priority pathogens in antimicrobial resistance 2019 ( EDCTP )

SCOPE: The purpose of this call for proposals is to provide funding for clinical trials to be conducted in sub-Saharan Africa which aim to develop new or improved medicinal products (drugs and vaccines) or combinations thereof against pathogens from the WHO priority list that also fall within the scope of the EDCTP2 programme, specifically Campylobacter, Salmonella, Streptococcus pneumoniae, and Mycobacterium tuberculosis. Proposals should include at least one clinical trial (phase I to IV) in sub-Saharan Africa. Proposals should clearly define the activities and mechanisms to be used within the project, including details of any collaboration with public authorities, international organisations or commercial partnerships that will be established in order to achieve the expected impact.

Open date: 3 June 2019, 00:00
Close date: 7 November 2019, 17:00

More information available here


Novo REPAIR Impact fund

World: Novo REPAIR Impact fund

SCOPE: The REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) Impact Fund will invest in start-ups, early-stage companies and corporate spin-outs in Europe and the United States. Their philosophy is to support ambitious programmes addressing antimicrobial resistance through a broad range of therapeutic modalities. The fund will focus on priority pathogens as defined by the World Health Organization and the United States Centers for Disease Control and Prevention, a catalogue of 12 families of bacteria that pose the greatest threat to human health. The fund is expected to invest USD 20 million to 40 million per year over 3–5 years in about 20 projects in Europe and the United States, which is anticipated to yield at least one new therapy reaching the market.

This is the fifth call for investment proposals since the REPAIR Impact Fund was set up in 2018. The fund has screened more than 180 investment proposals and invested in eight companies based in Europe and USA, all of which show great diversity of approaches to the scientific challenge of antimicrobial resistance. REPAIR has a total investment budget of EUR 135 million.


The Novo REPAIR Impact Fund is open from 8 June to 31 July 2020.
REPAIR’s commitment to funding the development of novel antibiotics will provide companies with the essential support to accelerate the development of early stage novel antibiotics towards the clinic to combat the growing threat of drug-resistant bacteria.
Companies are invited to submit a non-confidential proposal, which will be presented to the fund’s Scientific Selection Board and successful projects will be selected later in the year.

More information available here